Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479502 | 0.72 | CYP2C19 (0.37) | DYRK1ADYRK1B | |
| SCHEMBL3433360 | 0.71 | RET (0.31) | — | |
| SCHEMBL8319708 | 0.70 | DYRK1B (0.40) | DYRK1ADYRK1B | |
| SCHEMBL23199596 | 0.67 | DYRK1B (0.45) | DYRK1ADYRK1B | |
| SCHEMBL15726869 | 0.67 | PIM1 (0.45) | DYRK1ADYRK1B | |
| SCHEMBL8328800 | 0.67 | DYRK1A (0.52) | DYRK1ADYRK1B | |
| SCHEMBL8327596 | 0.67 | DYRK1A (0.38) | DYRK1ADYRK1B | |
| SCHEMBL20142243 | 0.67 | DYRK1A (0.35) | DYRK1ADYRK1B | |
| SCHEMBL4779596 | 0.67 | DYRK1A (0.38) | DYRK1ADYRK1B | |
| SCHEMBL4397083 | 0.67 | IMPDH2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070111996-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-17 | — | — | US | disclosed |
| US-7148228-B2 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050119282-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION | 2005-06-02 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119282-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | DYRK1A 3154/4885DYRK1B 3410/4885 |
| US-20070111996-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | DYRK1A 3154/4885DYRK1B 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.